2-Methoxymethyl-Salvinorin B Is a Potent κ Opioid Receptor Agonist with Longer Lasting Action in Vivo Than Salvinorin A
- 18 December 2007
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 324 (3), 1073-1083
- https://doi.org/10.1124/jpet.107.132142
Abstract
Salvinorin (Sal) A is a naturally occurring, selective κ opioid receptor (KOPR) agonist with a short duration of action in vivo. Pharmacological properties of a C(2) derivative, 2-methoxymethyl (MOM)-Sal B, were characterized. MOM-Sal B bound to KOPR with high selectivity and displayed ∼3-fold higher affinity than U50,488H [(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate] and Sal A. It acted as a full agonist at KOPR in guanosine 5′-O-(3-[35S]thio)triphosphate binding and was ∼5- and ∼7-fold more potent than U50,488H and Sal A, respectively. In Chinese hamster ovary cells stably expressing KOPR, all three κ agonists internalized or down-regulated KOPR to similar extents, with MOM-Sal B being the most potent. In mice, MOM-Sal B (0.05–1 mg/kg s.c.) caused immediate and dose-dependent immobility lasting ∼3 h, which was blocked by norbinaltorphimine. In contrast, ambulation in a Y-maze was increased when rats received MOM-Sal B (1–5 mg/kg s.c.). In addition, MOM-Sal B (0.5–5 mg/kg i.p.) produced antinociception (hot-plate test) and hypothermia in a dose-dependent manner in rats. MOM-Sal B was more potent than U50,488H in both tests and more efficacious than U50,488H in the hot-plate test. These latter two in vivo effects were blocked by norbinaltorphimine, indicating KOPR-mediated actions. Sal A at 10 mg/kg elicited neither antinociception nor hypothermia 30 min after administration to rats. In summary, MOM-Sal B is a potent and efficacious KOPR agonist with longer lasting in vivo effects than Sal A.This publication has 36 references indexed in Scilit:
- Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Preparation and Opioid Receptor Activity of Salvinicin AnaloguesJournal of Medicinal Chemistry, 2007
- Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of κ-Opioid Receptor-1 Knockout MiceThe Journal of pharmacology and experimental therapeutics, 2006
- Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonistPharmacology Biochemistry and Behavior, 2006
- κ-Opioid System in Uremic PruritusJournal of the American Society of Nephrology, 2005
- Pharmacokinetics of the plant-derived κ-opioid hallucinogen salvinorin A in nonhuman primatesSynapse, 2005
- Determination of Salvinorin A in body fluids by high performance liquid chromatography–atmospheric pressure chemical ionizationJournal of Chromatography B, 2005
- Agonist-induced regulation and trafficking of $kappa; opioid receptorsLife Sciences, 2004
- Salvinorin A, an Active Component of the Hallucinogenic SageSalvia divinorumIs a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional ConsiderationsThe Journal of pharmacology and experimental therapeutics, 2004
- Differential Regulation of the Human κ Opioid Receptor by Agonists: Etorphine and Levorphanol Reduced Dynorphin A- and U50,488H-Induced Internalization and PhosphorylationThe Journal of pharmacology and experimental therapeutics, 2003
- U50,488H-induced Internalization of the Human κ Opioid Receptor Involves a β-Arrestin- and Dynamin-dependent MechanismOnline Journal of Public Health Informatics, 1999